Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment

IF 2.1 4区医学 Q3 CLINICAL NEUROLOGY

Spinal cord Pub Date : 2023-12-29 DOI:10.1038/s41393-023-00952-9

Wen-Juan Ni, Xiao-Min Leng

{"title":"Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment","authors":"Wen-Juan Ni, Xiao-Min Leng","doi":"10.1038/s41393-023-00952-9","DOIUrl":null,"url":null,"abstract":"Diagnostic study. Programmed cell death 10 (PDCD10) is a new versatile molecule involved in signal transduction regulation in angiogenesis and tumors. The potential of using it as a biomarker for the diagnosis of ankylosing spondylitis (AS) is still unknown. University laboratory in Gannan Medical University, China. Expression of PDCD10 was analyzed using clinical samples of patients with AS and Gene Expression Omnibus (GEO) data GDS5231. To explore its function, PDCD10 was upregulated and downregulated in synovial cells. Spearman analysis was used to study the association between PDCD10 and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). The Receiver operating characteristic (ROC) curve was applied to evaluate the sensitivity and specificity of PDCD10. Expression of PDCD10 was upregulated in patients with AS and it is capable of promoting the calcification of synovial cells. A positive association between PDCD10 and the BASDAI and the mSASSS was observed. The area under the ROC curve (AUC) of PDCD10 was 82% with a 95% confidence interval of [0.772, 0.868]. PDCD10 is upregulated in patients with AS and it can promote the calcification of synovial cells in vitro. PDCD10 is positively associated with outcome parameters of AS. ROC analysis of PDCD10 suggests that it can be used as a biomarker for the diagnosis and treatment of AS.","PeriodicalId":21976,"journal":{"name":"Spinal cord","volume":"62 3","pages":"99-103"},"PeriodicalIF":2.1000,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spinal cord","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41393-023-00952-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diagnostic study. Programmed cell death 10 (PDCD10) is a new versatile molecule involved in signal transduction regulation in angiogenesis and tumors. The potential of using it as a biomarker for the diagnosis of ankylosing spondylitis (AS) is still unknown. University laboratory in Gannan Medical University, China. Expression of PDCD10 was analyzed using clinical samples of patients with AS and Gene Expression Omnibus (GEO) data GDS5231. To explore its function, PDCD10 was upregulated and downregulated in synovial cells. Spearman analysis was used to study the association between PDCD10 and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). The Receiver operating characteristic (ROC) curve was applied to evaluate the sensitivity and specificity of PDCD10. Expression of PDCD10 was upregulated in patients with AS and it is capable of promoting the calcification of synovial cells. A positive association between PDCD10 and the BASDAI and the mSASSS was observed. The area under the ROC curve (AUC) of PDCD10 was 82% with a 95% confidence interval of [0.772, 0.868]. PDCD10 is upregulated in patients with AS and it can promote the calcification of synovial cells in vitro. PDCD10 is positively associated with outcome parameters of AS. ROC analysis of PDCD10 suggests that it can be used as a biomarker for the diagnosis and treatment of AS.

Abstract Image

查看原文本刊更多论文

程序性细胞死亡 10 可用作诊断和治疗强直性脊柱炎的潜在生物标记物

研究设计诊断性研究。目的程序性细胞死亡10（PDCD10）是一种新的多功能分子，参与血管生成和肿瘤的信号转导调控。方法利用强直性脊柱炎患者的临床样本和基因表达总库（GEO）数据 GDS5231 分析 PDCD10 的表达。为了探究其功能，PDCD10在滑膜细胞中被上调和下调。斯皮尔曼分析用于研究PDCD10与巴斯强直性脊柱炎疾病活动指数（BASDAI）和改良斯托克强直性脊柱炎脊柱评分（mSASSS）之间的关联。结果PDCD10在强直性脊柱炎患者中表达上调，它能够促进滑膜细胞的钙化。PDCD10与BASDAI和mSASSS呈正相关。PDCD10的ROC曲线下面积（AUC）为82%，95%的置信区间为[0.772, 0.868]。PDCD10与强直性脊柱炎的预后参数呈正相关。PDCD10的ROC分析表明，它可作为诊断和治疗强直性脊柱炎的生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Spinal cord 医学-临床神经学

CiteScore

4.50

自引率

9.10%

发文量

142

审稿时长

2 months

期刊介绍： Spinal Cord is a specialised, international journal that has been publishing spinal cord related manuscripts since 1963. It appears monthly, online and in print, and accepts contributions on spinal cord anatomy, physiology, management of injury and disease, and the quality of life and life circumstances of people with a spinal cord injury. Spinal Cord is multi-disciplinary and publishes contributions across the entire spectrum of research ranging from basic science to applied clinical research. It focuses on high quality original research, systematic reviews and narrative reviews. Spinal Cord''s sister journal Spinal Cord Series and Cases: Clinical Management in Spinal Cord Disorders publishes high quality case reports, small case series, pilot and retrospective studies perspectives, Pulse survey articles, Point-couterpoint articles, correspondences and book reviews. It specialises in material that addresses all aspects of life for persons with spinal cord injuries or disorders. For more information, please see the aims and scope of Spinal Cord Series and Cases.